“London’s loss is Amsterdam’s gain. Today’s decision on the location of the European Medicines Agency means 1,000 high quality jobs leaving the UK, disrupting 1,000 families as a direct result of Brexit, with implications for thousands more. Businesses now need certainty," Steve Bates, the head of the British Industry Association commented. Pharma and biotech industry representatives seemed to be concerned that the ageny won't be able to continue its full services in a transition period due to staff loss. "It is vital that the relocation of the EMA will be carried out in such a way as to minimise as much as possible any disruptions that could negatively affect access to medicines for patients”, stressed John Brennan, Secretary General of EuropaBio, the European biotech indutry voice . "We hope that the EMA will be able to attract as many as of its staff as possible to relocate," added Birgit Fischer, Head of German Pharma association VFA.